[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-343156-105":59,"doc-detail-343156-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","cannabinoids-and-triple-negative-breast-cancer-treatment-review","Cannabinoids and triple-negative breast cancer treatment - Review","","Triple-negative breast cancer (TNBC) accounts for about 10–20% of breast cancer and carries the worst prognosis, historically with limited options centered on chemotherapy. Immunotherapy with immune checkpoint inhibitors has improved systemic treatment, yet requires new tumor-specific biomarkers to better predict outcomes. Cannabinoids display antitumor activity in most preclinical TNBC models without apparent chemotherapy-related adverse effects. The endocannabinoid system links to immunity and immunosuppression, so cannabinoid receptors may serve as biomarkers for immune checkpoint inhibitor therapy or as a mechanism to overcome immunotherapy resistance. This review summarizes current knowledge on how cannabinoids may influence standard TNBC treatment.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cannabinoids-and-triple-negative-breast-cancer-treatment-review/343156/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cannabinoids-and-triple-negative-breast-cancer-treatment-review/343156.png","ImageObject",300,407,{"name":92,"@type":93},"Theodore","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is triple-negative breast cancer (TNBC) and why is it clinically challenging?","Question",{"text":112,"@type":113},"TNBC is defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and HER2, and it accounts for about 10–20% of cases. It is associated with the worst prognosis and historically has had limited treatment options.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How have immune checkpoint inhibitors changed TNBC treatment?",{"text":117,"@type":113},"Immunotherapy using inhibitors of PD-L1 and PD-1 (immune checkpoint inhibitors) is a new successful systemic treatment option. Atezolizumab and pembrolizumab are used in clinical practice for metastatic or early-stage settings based on PD-L1 or CPS criteria.",{"name":119,"@type":110,"acceptedAnswer":120},"What role might cannabinoids play in TNBC therapy?",{"text":121,"@type":113},"Cannabinoids show antitumor activity in most preclinical TNBC models and have not appeared to worsen chemotherapy effects. Because the endocannabinoid system is linked to the immune system and immunosuppression, cannabinoid receptors may become biomarkers for checkpoint inhibitor therapy or help reverse resistance.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},343156,1790168363,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","TYPE Review  \nPUBLISHED 08 August 2024  \nDOI 10.3389/fimmu.2024.1386548  \nOPEN ACCESS  \nEDITED BY  \nXiangyi Kong,  \nChinese Academy of Medical Sciences and Peking Union Medical College, China  \nREVIEWED BY  \nMarialessandra Contino, University of Bari Aldo Moro, Italy Nabanita Chatterjee,  \nThe Ohio State University, United States  \n*CORRESPONDENCE Simona Kranjc Brezar  \n [skranjc@onko-i.si](skranjc@onko-i.si)  \nRECEIVED 15 February 2024  \nACCEPTED 15 July 2024  \nPUBLISHED 08 August 2024  \nCITATION  \nDoboviˇsek L, Borˇstnar S, Debeljak N and Kranjc Brezar S (2024) Cannabinoids and triple-negative breast cancer treatment. Front. Immunol. 15:1386548 .  \ndoi: 10.3389/fimmu.2024.1386548  \nCOPYRIGHT  \n© 2024 Doboviˇsek, Borˇstnar, Debeljak and Kranjc Brezar. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nCannabinoids and triple-negative breast cancer treatment  \nLuka Doboviˇsek 1, Simona Borˇstnar 1, Nataˇsa Debeljak 2 and Simona Kranjc Brezar 3,4*  \n1 Division of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia, 2 Medical Centre for Molecular Biology, Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia, 3 Department of Experimental Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia, 4 Faculty of Medicine, University of Ljubljana,  \nLjubljana, Slovenia  \nTriple-negative breast cancer (TNBC) accounts for about 10-20% of all breast cancer cases and is associated with an unfavorable prognosis. Until recently, treatment options for TNBC were limited to chemotherapy. A new successful systemic treatment is immunotherapy with immune checkpoint inhibitors, but new tumor-speciﬁc biomarkers are needed to improve patient outcomes. Cannabinoids show antitumor activity in most preclinical studies in TNBC models and do not appear to have adverse effects on chemotherapy. Clinical data are needed to evaluate efﬁcacy and safety in humans. Importantly, the endocannabinoid system is linked to the immune system and immunosuppression. Therefore, cannabinoid receptors could be a potential biomarker for immune checkpoint inhibitor therapy or a novel mechanism to reverse resistance to immunotherapy. In this article, we provide an overview of the currently available information on how cannabinoids may inﬂuence standard therapy in TNBC.  \nKEYWORDS  \ntriple-negative breast cancer, cannabinoids, endocannabinoid system, chemotherapy, immunotherapy, immune system, tumor microenvironment, immune checkpoint inhibitors  \n1 Triple-negative breast cancer  \nTriple-negative breast cancer (TNBC) accounts for about 10-20% of all breast cancer cases and is associated with the worst prognosis. TNBC is a heterogeneous group of tumors deﬁned by the absence of the estrogen receptor (ER), the progesterone receptor (PR), and the absence of the human epidermal growth factor receptor 2 (HER2) . It mainly occurs in younger patients and patients with BRCA germline mutations (1, 2) . TNBC has been divided into six different subgroups: basal-like 1 (BL1), basal-like 2 (BL2), mesenchymal (M), mesenchymal stem-like (MSL), immunomodulatory (IM) and luminal androgen receptor (LAR) (3) . The TNBC microenvironment (TME) includes tumor-inﬁltrating lymphocytes (TILs) with CD3+ T and CD20+ B lymphocytes, CD38+/CD138+ plasma cells, tumor-associated macrophages (TAMs), cancer-associated ﬁbroblasts (CAFs), tumorassociated neutrophils (TANs), natural killer (NK) cells and cancer-associated adipocytes (CAAs) . The TNBC TME is unique in that it has a high expression of vascular endothelial growth factors ","cbCaivqSPUqdTSgQ","https://ap.wps.com/l/cbCaivqSPUqdTSgQ","pdf",1367208,13,"English","# Triple-negative breast cancer\n## Immune checkpoint inhibitors and current treatment landscape\n## TNBC tumor microenvironment and immune cells\n# Cannabinoids and the endocannabinoid system in TNBC\n## Potential biomarkers and mechanisms for immunotherapy response\n# Clinical evidence needs and safety/efficacy considerations","[{\"question\":\"What is triple-negative breast cancer (TNBC) and why is it clinically challenging?\",\"answer\":\"TNBC is defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and HER2, and it accounts for about 10–20% of cases. It is associated with the worst prognosis and historically has had limited treatment options.\"},{\"question\":\"How have immune checkpoint inhibitors changed TNBC treatment?\",\"answer\":\"Immunotherapy using inhibitors of PD-L1 and PD-1 (immune checkpoint inhibitors) is a new successful systemic treatment option. Atezolizumab and pembrolizumab are used in clinical practice for metastatic or early-stage settings based on PD-L1 or CPS criteria.\"},{\"question\":\"What role might cannabinoids play in TNBC therapy?\",\"answer\":\"Cannabinoids show antitumor activity in most preclinical TNBC models and have not appeared to worsen chemotherapy effects. Because the endocannabinoid system is linked to the immune system and immunosuppression, cannabinoid receptors may become biomarkers for checkpoint inhibitor therapy or help reverse resistance.\"}]","Cannabinoids and triple-negative breast cancer treatment - Review | PDF",1790050132,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e9bf17ccdc686cedcdc8886b40bd726f.webp",983,1389,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bd42cd7127566e5fdcfaa3404c2f6c43.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/458dc3cf3db9d6ada89fe75a5395efb7.webp",981,1386,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/268bef08860c5ab532a6e427845098e9.webp",980,1385]